NCL News Archive

Friday, October 26, 2018

Licensing Opportunity: Novel Scavenger Receptor A1-Targeted Macromolecular Prodrug Platform

Investigators at the NCL have developed a drug delivery platform that targets scavenger receptor A1, a receptor highly expressed in macrophages, monocytes, mast cells, and dendritic cells (myeloid lineages), as well as endothelial cells. The platform is based on the anionic polymer poly(L-lysine succinylated), which contains side chains with pendant carboxylic acids that allow conjugation of... View Post


Thursday, October 18, 2018

Changes to NCL Application Due Dates for 2019

Beginning in 2019 the NCL will accept applications twice per year, a change from previous years in which applications were accepted quarterly. The due dates for applications will be the first business days of March and September.

For those of you still hoping to apply this year, we are still accepting December applications this year, with the due date... View Post


Thursday, October 11, 2018

August 2018 Awardees Announced

Each quarter the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and... View Post


Tuesday, July 31, 2018

AAAS highlights NCL, UNC-Charlotte, Ball State collaboration

AAAS recently highlighted work conducted as part of a longstanding collaboration between NCL, the University of North Carolina-Charlotte and Ball State University, investigating immune responses to nucleic acid-based nanoparticles. The project has been led by Dr. Marina Dobrovolskaia, Sr. Principal Scientist at NCL and Prof. Kirill Afonin, UNC-Charlotte, and describes a recent Nano Letters... View Post


Friday, June 29, 2018

NANOBIOTIX Announces Positive Phase II/III Results with NBTXR3

Nanobiotix, a former NCL collaborator and Assay Cascade awardee, recently announced positive results from a phase 2/3 study of NBTXR3 in soft tissue sarcoma. NBTXR3 (hafnium oxide nanoparticles) combined with radiotherapy showed a better response than radiotherapy alone in a trial of 180 patients. From the Nanobiotix website:

Trial achieved its primary endpoint of pathological Complete... View Post


Thursday, June 28, 2018

AAPS Forum on FDA Guidances

A Guidance Forum Workshop, presented by AAPS, will take place September 11-12, 2018, in Silver Spring, MD. The focus of the workshop will be to discuss challenges, issues and concerns for the FDA guidance documents that are most important to AAPS members. From a poll of stakeholders, two guidance documents have been selected for this forum:

Drug products... View Post


Monday, June 4, 2018

FDA Guidance on Liposome Drug Products

The FDA recently finalized a guidance for industry document on liposome drug products. The guidance focuses on the chemistry, manufacturing and controls; human pharmacokinetics and bioavailability; and labeling documentation.

The guidance document can be downloaded from the FDA’s website here: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/... View Post


Monday, June 4, 2018

Nanoparticle Inhibits Growth of Pancreatic Cancer in Mice

A novel polyplex nanoparticle formulated at the NCL is shown to inhibit growth of pancreatic cancer and prevent metastasis in mice. The study was co-lead by Dr. Jill Smith of Georgetown University and Lombardi Comprehensive Cancer Center and NCL’s Pharmacology and Toxicology Section Head Dr. Stephan Stern. The results of the study were recently published in Cellular and Molecular... View Post


Monday, May 7, 2018

May 2018 Awardees Announced

Each quarter the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and... View Post


Friday, April 6, 2018

Opening for a Formulation Scientist

The Nanotechnology Characterization Lab (NCL) provides nanotechnology formulation and characterization services for universities, the pharmaceutical industry and other government programs. Since our founding in 2004, the NCL has characterized more than 400 different nanomedicines for more than 100 organizations worldwide. We are currently seeking a Formulation Scientist to... View Post


Pages